Posted by Michael Wonder on 08 May 2023
Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
8 May 2023 - First and only approved treatment in China for rare and progressive genetic condition, which can result in growth of benign tumours along nerves throughout the body.
Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 aged three years and above.
